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Migration from different parts of the world to several European countries leads to the introduction of haemoglobinopathy genes
into the population, which creates several demanding needs for prevention and treatment services for Hb disorders. In this paper
we examined the degree to which European health services have responded to such challenges and in particular to health services
necessary to address the needs of patients with thalassaemia and sickle cell disease (SCD). Information on available services was
obtained from international organizations, collaborated European project, and the Thalassaemia International Federation (TIF)
Databases,whichincludeinformationfrompublishedsurveys,registries,fieldtrips,anddelegationvisitstocountriesandregionsby
expert advisors, local associations, and other collaborators’ reports. Results show that countries with traditional strong prevention
and treatment programs are well prepared to face the above challenges, while others are urgently needed to address these problems
in a systematic way. The Thalassaemia International Federation (TIF) is committed to monitor the progress, raise awareness,
and support the promotion of more immigrant-oriented health policies to ensure their integration in society and their access to
appropriate, adequate, and timely health services.
1. Introduction
Throughout history, poverty, land pressures, climate change,
famine, war, and persecution have forced people to move
from their homeland and in this context migration is not at
a l ln e w .M i g r a n t s ,l i k ea l lp e o p l e ,c a r r yw i t ht h e mp e r s o n a l
health prints made up of ethnic and family disease suscepti-
bilitiesandreflectthewaysinwhichpeopleandcultureshave
adapted to their physical environment and the mechanisms
they have developed to deal with illness. As such, free pop-
ulation movements have always been considered important
challenges to global health. Today as the gap between rich
and poor countries is growing, people are moving faster
and further, crossing vast climate and “disease zones”, being
forced, in greater numbers, to seek work and better life
e l s e w h e r e .A tt h es a m et i m er i c h e rc o u n t r i e sa r ea c t i v e l y
recruiting people to address their emerging labour needs
while modern means of transportation and communication
makeitmucheasierforpeopletomigratewhileseekingbetter
opportunities in life.
Population movements have had a major impact on
disease epidemiology and public health. In the past, the
main concern has been the spread of communicable diseases
linked to poverty, suboptimal hygiene conditions, and lack2 The Scientific World Journal
of contemporary prevention programs and public health
services. The more recent migration process observed in the
end of the twentieth and dawn of the twenty-first century
continues to contribute to the spread of communicable
diseases but have in addition resulted in dramatic changes in
the epidemiology of chronic diseases previously unknown or
of low prevalence in host populations. These new “imports”
represent a significant additional challenge to health services
on a global scale.
Migrants experience a unique journey linked to the
classical four phases of migration: premigration preparation,
arrival,integration,andreturn.Withoutunderestimatingthe
significance of all stages of migration, during the arrival
and integration phase, poverty and social exclusion are
considered to exert their greatest effect on individual and
group health outcomes. This is the period when the health of
migrantsisinfluencedbytheavailability,accessibility,accept-
ability, and quality of services in the new host environment.
Health services may not be accessible because of linguistic,
cultural, religious, and social barriers and this situation may
sadly persist for many years after their establishment in the
new host country.
The above were clearly evidenced in countries which
traditionally hosted immigrants from countries where Hb
disorders have been highly prevalent including UK, where
in 2000 it was shown that despite available quality health
services for prevention, screening, and care, there was only
50% uptake of such services by immigrants [1]a n do n l y5 0 %
chance of survival of patients with 𝗽-thalassaemia major at
the age of 35 [2]. The UK presents an example of a country
where, today, third- or fourth-generation immigrants, from
haemoglobinopathy prevalent countries, live and work and
despite this, it was not until such data were analyzed that
national strategies for these diseases were put in place.
The global geographical distribution of the haemo-
g l o b i n o p a t h yg e n e si st o d a yw e l ld o c u m e n t e d[ 3, 4]a n di t
i sw e l lk n o w nt h a ti nE u r o p e ,s u c hg e n e sa r ee n d o g e n o u s
mainly in the populations of the south, especially in the
countries of the Mediterranean basin and to a lesser extent
in some of the countries of Eastern Europe. In contrast,
these genetic traits are quite rare in the western, central,
and northern countries of the European Continent. Migrants
fromtheMiddleEast(ME),SouthEastAsia(SEA),andother
mainly malaria-endemic (or previously endemic) countries
of the world have been moving, over the 20th century, to the
western partof Europe.In additionmigrantsfromtheSouth,
previously less affluent countries of Europe, have also been
migratingtowardsWestandNorthEurope.Suchpopulations
have now reached their second, third, or even fourth gener-
ation in these countries. In more current years, however, the
immigration statistics are dramatically changing. There has
been a substantial increase of population movements from
ME, Asia, and Africa, much less from the south of Europe,
a n dm o r ef r o mt h eE a s t e r nE u r o p e a nc o u n t r i e sw h oh a v e
recently gained accession to the European Union (EU). Host
countries in the last decade include mainly the fifteen old
states of the EU [5]. These changes bring about considerable
challengestoallsystemsofthehostcountriesincludingmost
importantly their health services system.
I nthisstudyweha veeval ua tedthedegr eetowhichE ur o-
peanhealthserviceshaverespondedtosuchchallengesandin
particular to health services necessary to address the control
of rare anaemias and more specifically of haemoglobin
disorders (Hb disorders): thalassaemia and sickle cell disease
(SCD). We have focused on the compilation and analysis of
the current status of services in specific European countries
that appear to receive the majority of migrants from high-
prevalence areas.
2. Methods
2.1. Countries. I nt h i ss t u d yw eh a v ei n c l u d e d1 2E u r o p e a n
countries: Austria, Belgium, Cyprus, Denmark, France, Ger-
many, Greece, Italy, The Netherlands, Spain, Sweden and the
United Kingdom (UK).
2.2. Criteria. In order to examine the impact of Hb dis-
orders on the health services, we examined the specific
control programs for such health issues, which have literally
been introduced through long-term and recent migration in
almost every European country. Such assessment required
the gathering of information on the following aspects of
migration:
(i) the size and origin of each migrant group or ethnic
minority in each host country and whether these are
permanent or temporary workers/residents;
(ii) the expected contribution of migrant groups to the
haemoglobinopathy gene pool in the new host coun-
try;
(iii) the marriage and reproductive behaviour of the new
population groups versus the second, third (or more)
generation of immigrants.
In addition, the services were evaluated having in mind
the needs of those affected by such disorders. The services to
be provided and planned for are those that aim at the best
possible survival and quality of life of patients. These include
preventive measures which will allow informed choices by
risk couples from these communities. In considering the
needs for health care services, the rarity of the conditions
in many countries was taken into account. Service needs
according to published best practice guidelines [6]w e r e
built mainly on knowledge and experience derived from
successful control programs implemented in some countries.
The characteristics of such programs include
(i) spread of community awareness, education, screen-
ing, and counselling,
(ii) availability of possible solutions such as prenatal
diagnosis or preimplantation diagnosis as available
choices for informed couples,
(iii) neonatal screening programs for sickle cell disease,
(iv) system capacities to provide timely and accurate
diagnosis,
(v) provision of medical and other care and monitoring,The Scientific World Journal 3
(vi) provision of multidisciplinary care in expert cen-
tres with effective networking of centres within and
between countries to support primary and secondary
level services,
(vii) education of the medical and patients’ communities.
I no r d e rt oa c h i e v et h ea b o v eo b j e c t i v e s ,a p p r o p r i a t e
public health and services planning were assessed regarding
the existence of national policies to address the control of
haemoglobin disorders, are regarded as essential. National
policies may be disease specific as for example in a disease
management programs (Cyprus, Italy, and Greece), under
a general plan for rare diseases, or for chronic diseases in
general (France).
2.3. Sources of Information. Since all Hb disorders and other
rare anaemias are usually treated by the same clinical and
public health services, it was possible for TIF, both through
its own work and also through its partnership with national
and international organizations and projects, to evaluate
the current situation of services for Hb disorders and by
extension for other rare congenital anaemias in European
communities. In order to have a clear picture of the situation
and to advocate for the development of services where they
are most needed, TIF has developed, over the past few years,
a global database for Hb disorders, which includes not only
informationontheburdenofdiseaseineachcountry ,butalso
onavailable services andontheextent ofaccess ofpatientsto
free and comprehensive care within national health systems.
Having in mind the resources required for lifelong care,
the existence of prevention measures as a tool to save and
r e a l l o c a t er e s o u r c e si sa l s oe x a m i n e di nt h i ss t u d y .I no r d e r
to estimate the magnitude of the problem the following
parameters, numbers, and estimates were considered.
(1)ThenumberofimmigrantsineachEuropeancountry ,
whose origin is from countries or populations with a
thalassaemia and SCD carrier rate of more than 1%.
Theinfluxfromcountrieswithalowprevalenceisnot
included in our estimates and the major source of the
data is the Eurostat Population Database [7].
(2) The carrier rate in each ethnic groupwhich is derived
from the carrier rate in the country of origin was
used to estimate the number of carriers within each
group. This was then added to the carrier rate of
the indigenous population (for the low-prevalence
countriesthecarrierrateisassumedtobe0.1%unless
more accurate details are known) [5].
(3) Carrier rates and other figures were taken from
the Thalassaemia International Federation (TIF)
Databases, which include information from pub-
lished surveys, registries, field trips, and delegation
visits to countries and regions by expert advisors,
local associations, and other collaborators’ reports.
On occasions, reports were used from industry and
national/regionalhealthauthoritiesandfromrelevant
scientific conferences. In this database most African
and American continents data are incomplete and
were thus supplemented from the modell’s almanac
[8].
(4) From the total carriers calculated as described above,
the expected annual affected births were estimated
according to the Hardy-Weinberg rule [9].
(5) The disease burden was completed by recording the
number of known patients in each country. The
numberwasagainobtainedfromTIFmemberassoci-
ations, published information, and national registries
wherever possible.
3. Results
Assessment of the quality of services currently available in
each country has been made possible through the work of
ENERCA and the funded project from the Executive Agency
forHealthandConsumers.Thisfundingwasprovidedforthe
preparationoftheWhiteBookontheidentificationofthecri-
teria for haemoglobinopathy reference centres and networks
i nt h eE u r o p e a nU n i o n .Th i sW h i t eB o o ki n c l u d e ss e v e r a l
components such as the existence of national and regional
health policies supporting services for haemoglobin disor-
ders,theassessmentofacomprehensivediseasemanagement
policy for chronic and/or rare diseases. The existence of
a national policy for prevention of thalassaemia including
education,screening,counselling,andprenataldiagnosis,the
establishment of a neonatal screening program for sickle cell
disease, and the institution of a health insurance policy that
allowsfreecoverageforchronicdiseasepatients,ascompared
to partial coverage that requires out-of-pocket expenses.
In Table 1 we present several estimations for the number
of Hb disorder carriers in different European countries.
The results are presented to the nearest figures that were
calculated on the available data on immigrant populations.
It was assumed that Northern European populations have
a thalassaemia carrier rate of 0.1% in their indigenous
populations and no carriers of the sickle cell gene [3]. The
importance is that in the countries where the prevalence
is high in the indigenous population (Cyprus, Greece, and
Italy) there are national policies to meet the needs of these
disorders.IntherestofEurope,theproportionofimmigrants
is approximately similar, yet only the UK and France have
disease-specific policies. The carrier frequency is rising most
rapidlyinBelgiumandSpainwherenationalplanningismost
urgently needed.
In Table 2 we present the disease burden from Hb
disorders in each country under investigation in relation
to the number of expected births and the number of
known patients. In Table 3 we delineate the different health
policies that constitute a prerequisite for the development
and provision of diagnostic and clinical services to such
patients, while in Table 4 we provide information regarding
the most important prevention services available. In Table 5
we examine the different diagnostic and clinical services
offered in each country such as designated treatment centres,
reference laboratories, and the existence of specialized tests
for treatment, including cardiac monitoring with magnetic
resonance imaging (cardiac MRI T2
∗) for the assessment of4 The Scientific World Journal
Table 1: Estimations of the number of carriers in the countries studied.
Country Total
population
Total number
of immigrants
carriers of 𝗽-
thalassaemia
Total number
of carriers of
b-thalassaemia
in the
indigenous
population
Total number
of immigrant
carriers of
HbE
Total number
of immigrants
carries of
sickle cell
Total number
of immigrant
carriers of
HbC
Carrier
immigrants as
a proportion
of the total
population
Carriers of Hb
disorders as a
proportion of
the total
population
(1) Austria 8210281 11842 8210 2453 4675 708 0.24% 0.34%
(2) Belgium 10438353 19403 10438 4073 39250 5169 0.65% 0.75%
(3) Cyprus 840407 3991 121019 354 583 20 0.58% 15%
(4) Denmark 5543453 6772 5543 4083 2277 330 0.24% 0.34%
(5) France 64057792 98219 64058 32607 172600 47884 0.54% 0.65%
(6) Germany 82329758 128419 82330 22955 53883 7135 0.25% 0.36%
(7) Greece 10737429 29289 837519 536 7626 183 0.35% 8.70%
(8) Italy 61261254 75748 2572972 9463 72870 21416 0.29% 6.50%
(9) The
Netherlands 16715999 27656 16716 13751 30329 7703 0.47% 0.57%
(10) Spain 47042984 57257 715053 2434 92601 27796 0.38% 1.90%
(11) Sweden 9482855 21092 9483 12593 8720 912 0.46% 0.56%
(12) UK 63047162 107694 63047 27124 145038 25290 0.48% 0.58%
Th e s er e s u l t sa r et h en e a r e s tfi g u r e st h a ta r ec a l c u l a t e do nt h ea v a i l a b l ed a t ao ni m m i g r a n tp o p u l a t i o n s .I tw a sa s s u m e dt h a tN o r t h e r nE u r o p e a np o p u l a t ions
have a thalassaemia carrier rate of 0.1% in their indigenous populations and no carriers of the sickle cell gene. The importance is that in the countries where
the prevalence is high in the indigenous population (Italy, Greece, and Cyprus), there are national policies to meet the needs of these disorders. In the rest of
Europe the proportion of immigrants is approximately similar, yet only the UK and France have disease specific policies. The carrier frequency is risingm o s t
rapidly in Belgium and Spain where national planning is most urgently needed.
cardiac iron load in regularly transfused patients and the
transcranial doppler (TCD) to assess stroke risk in sickle cell
patients.
In Figure 1 we clearly see that thalassaemia and/or sickle
cell disease genes are more common among the immigrant
groups of European countries, and the gene predominance
reflects the origin of the immigrant groups residing in each
country. The increase in migrations from sub-Saharan Africa
for example is seen in Belgium, France, Spain, Italy, and
the UK, while other countries are influenced by migrations
from Southern and Eastern Europe, West Pacific, and Asia
such as Spain and France. The trend of accelerated influx of
migrantpopulationsfromhigh-prevalenceareas is presented
in Figures 2 and 3, comparing the migrant populations
between 2001 and 2011 in Belgium and Spain, respectively.
S u c ht r e n d sa r es e e ni nm o s tE u r o p e a nc o u n t r i e sa n dt h o s e
of African descent seem to be increasing at a faster rate.
4. Discussion
The Thalassaemia International Federation (TIF) constitutes
an international federation of 110 national patient support
organizations from 60 countries around the world. Its mis-
sion is to support the development and implementation
of national control and prevention programs and promote
optimal management for Hb disorders. The ultimate goal is
to secure equal access to quality health care for all patients
with Hb disorders around the world.
TIF works in close and official relations with WHO
headquarters and regional offices, promotes the two WHO’s
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Figure 1: Relative proportion of carriers of Hb disorders among
immigrant populations in selected European Countries. The
denominator used included the total number of carriers of Hb
disorders in each country.
specific resolutions on thalassaemia and SCD, and sup-
ports WHO’s plan of action for Noncommunicable Diseases
(NCDs) and the inclusion of these diseases into the national
policiesforNCDs.TIFisalsoactiveinEurope,supportingtheThe Scientific World Journal 5
Table 2: Disease burden with the expected births and the number of known patients.
Countries Expected thalassaemia
births/1000 live births
Expected SCD
births/1000 live births
Number of known or estimated
patients with thalassaemia
syndromes
Number of known or estimated
patients with sickle cell
syndromes
(1) Austria 0.0015 0.00008 NA NA
(2) Belgium 0.002 0.0035 100 400
(3) Cyprus 5.5 0.0018 639 40
(4) Denmark 0.0018 0.00004 NA NA
(5) France 0.0016 0.0018 571 10000
(6) Germany 0.0016 0.0001 1500 3000
(7) Greece 1.6 0.009 3241 1080
(8) Italy 0.46 0.11 7000 6000
(9) The
Netherlands 0.0018 0.0008 250 750
(10) Spain 0.067 0.0011 113 >200
(11) Sweden 0.0025 0.00021 50 100
(12) UK 0.0018 0.0013 920 15000
Table 3: Health policies which support services.
Country National register
for Hb disorders
Hb disorders under
national policy: chronic
diseases
Hb disorders under
national policy: rare
diseases
Hb disorders under
national policy: Blood
diseases
National policy
for prevention
(1) Austria No No
(2) Belgium No No No No No
(3) Cyprus Yes Special policy Yes
(4) Denmark No No No No No
(5) France Yes Yes Yes
(6) Germany Initiated Special policy No
(7) Greece Yes Special policy Yes
(8) Italy Yes (regional) Special policy Yes
(9) The
Netherlands Initiated No No No Yes
(10) Spain Regional No Yes No No
(11) Sweden No No No No No
(12) UK Yes Special policy Yes
inclusionandpromotionofHbdisordersintothecommunity
actionandCouncilRecommendationsonRareDiseases[10–
12] .M a n yo t h e rr e l e v a n tW o r l dH e a l t hA s s e m b l yr e s o l u t i o n s
have been supported by TIF including those on the control
of birth defects, viral hepatitis, health inequalities, social
determinants of health and the haemoglobin disorders [13,
14].
In the above context, TIF supports the transposition of
the EU Directive on Patients’ rights for Cross Border Health
Careintonationallegislation.Mostimportantly,itisinvolved
in the promotion and networking of Reference Centres for
Rare Diseases, including Hb disorders, which are amongst
the prerequisites of the above directive. In addition, TIF
operatesonitsownplanofactivities,includingitseducational
program, and participates in relevant EU projects such as
Ithanet and ENERCA. Awareness and education of patients
and health professionals is also achieved through the above
information and organization networks.
With regards to immigrant groups information, there are
severalreasonswhymuchorpartofitmaybeapproximations
u n d e r -o ro v e r e s t i m a t e d .Th eq u a l i t yo fa v a i l a b l ed a t ao n
carriers for example is often based on outdated, inappropri-
ately sampled studies and/or small local surveys referring to
selected groups rather than representing total populations.
However we have used the best possible estimates derived
n o to n l yf r o mp u b l i s h e dd a t ab u ta l s of r o mT I F ’ sd a t a b a s ea s
described before.
The effect of migrations cannot be assessed only on
t h en u m b e r so fm i g r a n t s .Th eb e h a v i o u ro ft h e s eg r o u p s
in terms of marriage, reproduction, use of health services,
permanency in the new host country, and other sociological
factors also needs to be studied and considered. For example,6 The Scientific World Journal
Table 4: Policies and available prevention services.
Country Carrier screening available Carrier screening free Neonatal screening Prenatal diagnosis available
(1) Austria No No No No
(2) Belgium Yes No Regional Yes
(3) Cyprus Yes Yes No Yes
(4) Denmark
(5) France Targeted Yes Regional Yes
(6) Germany No No No Yes
(7) Greece Yes Yes No Yes
(8) Italy Yes Yes Regional Yes
(9) The Netherlands Yes Yes Yes
(10) Spain Regional Yes Regional No
(11) Sweden No No No
(12) UK Yes Yes Yes Yes
Table 5: Diagnostic and screening services.
Country Designated treatment centres
serving all patients
Reference labs Networks of labs MRI T2
∗ TCD
(1) Austria No No No No
(2) Belgium Majority Yes No No Yes
(3) Cyprus Yes Yes Yes Yes No
(4) Denmark No No No
(5) France Yes Yes Yes Yes Yes
(6) Germany Minority Yes Yes Yes
(7) Greece Yes Yes Yes Yes No
(8) Italy Yes Yes Yes Yes Yes
(9) The Netherlands No Yes Yes No
(10) Spain Minority Yes Yes
(11) Sweden No No No
(12) UK Yes Yes Yes Yes Yes
intermarriage with the host population is certainly observed
to occur as well as marriage with other ethnic minorities;
however these parameters are not usually officially recorded
in most countries. For instance, of the approximately 10.000
Filippino residents (potential carriers of both thalassaemia
and HbE, which is nonexistent in the Cypriot population) in
Cyprus in 2011, 7.702 are between the ages of 15 and 44 and
513 women were married in Cyprus in the last 4 years. These
are females who come to Cyprus as domestic workers on a
four-year contract. None was married to a countryman of
theirs,56%weremarriedtoaCypriot,and23%weremarried
to a husband from another thalassaemia-prevalent country
(the chances of a Cypriot-Filippino marriage producing an
affected offspring are roughly 1:1.750). This is an indication
that not all “temporary” migrants return to their home
country.Suchsocialvariablescannotalwaysbeestimatedand
the example from Cyprus was chosen because of the readily
available data from a small country.
Another variable whose effect can only be approximated
is the contribution of nonregistered migrants who are esti-
mated to be 1–4% of the population in Europe. This group
will face all the problems of their “legal” counterparts and in
addition will have to face even more difficulties in accessing
the new host countries’ health services because of fear of
exposure. Where a chronic disease is concerned, the prob-
lems seem insurmountable and the help of NGOs which may
step in to give assistance (http://www.nowhereland.info/)i s
usually very limited.
Another difficulty in assessing the importance of migra-
tion on the national and EU burden of these diseases is
that the majority of European countries do not maintain
comprehensive registries of patients, that include diagnosis,
agedistribution,locationwithinacountry,dataonnewcases,
complication rates, and mortality data. One of the objectives
of the current work is to highlight this problem and alert
national health policy makers to the need for promoting
nationalpoliciesforHbdisordersandfortheimprovementof
accessandintegrationofimmigrantpatientstotheseservices.
Specific health services registries are considered essential
t op r o v i d ee ff e c t i v ep l a n n i n g .I nf a c t ,i ti sq u i t ed i ffi c u l tt o
understand how appropriate multidisciplinary services may
bedevelopedandprovidedinordertocovertheneedsofsuch
patients in the absence of such information. Thus, one may
argue that the lack or existence of a registry is indeed a majorThe Scientific World Journal 7
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Figure 2: Increase in the number of immigrants carrying Hb
disorders in Belgium between 2001 and 2011 according to the
geographic region of origin.
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Figure 3: Increase in the number of immigrants carrying Hb dis-
orders in Spain between 2001 and 2011 according to the geographic
region of origin.
i n d i c a t o ro ft h eq u a l i t yo fc a r ei ne a c hc o u n t r y .R e g i s t r i e s
for Hb disorders exist currently only in France [15], Greece
[16], Cyprus [17], Italy [18], and UK [19, 20]. Each of these
referenced articles also demonstrates the usefulness of the
derived information from national registries. The rest of the
countries in this study provide estimates of the numbers of
patients which, however, cannot be reliably confirmed.
In considering the services for chronic Hb disorders and
their poor or limited uptake by the immigrant populations,
o n em a ye l a b o r a t eo nt w om a j o rr e a s o n s .F i r s tt h e r ea r e
constraints which originate from the social situation of the
m i g r a n tg r o u p si nah o s tc o u n t r y ,t h el o we d u c a t i o n a ll e v e l
especially of the new or first-generation migrants along with
language and cultural barriers. Where hereditary disorders
are concerned, there are also additional factors such as
ignorance of the condition and its causes, including the
possibility of carrier testing [21–24], social prejudice, and
cultural and religious attitudes towards prevention and preg-
nancy termination. On many occasions, priority is rightly
given to more acute problems related to family survival and
occupational settlement in the new host country. The second
factor is the response of health services in the host country
to health problems which are initially and largely unknown
and perhaps “foreign” to the indigenous population and not
included in planning and policy making. The extent of the
problem is usually only made known over time, since only
a few such patients appear in hospital paediatric or adult
departments and are considered as isolated cases.
Although, in more recent years, the importance of
developing and implementing national programs in every
EU member state by 2013 for rare diseases has been very
much underscored, still to date surveys are generally lacking.
Early diagnosis is often delayed and appropriate services
for management are still largely absent or heterogeneously
spread across, between and within European countries. In
addition, strategic prevention of these disorders, in the vast
majority of EU countries, is still absent at the national or
regional level.
ItisquiteinterestingthatMediterraneancountries,which
have a high prevalence of haemoglobinopathy genes in the
indigenous population, are in recent years receiving immi-
grant groups from other high-prevalence countries. These
countries, namely, Italy, Greece, and Cyprus, already have an
infrastructure for the comprehensive management of these
disorders with a long history of service development [25–
27]. In these countries new affected births were drastically
reducedbynationallycontrolledpreventionprogramsmainly
instituted by late 1980s. In recent years, however, the affected
b i r t h sa r es e e nt ob er i s i n gd u et ot h ep o o rr e s p o n s eo ft h e
“new” immigrant groups as evidenced from the experience
in Latio, Italy [28]. The question arises as to why these
population groups do not take advantage of established pre-
vention programs and health services. The most important
reasons possibly relate to the lack of awareness of these
immigrantsforsuchprogramsduetotheabsenceofprevious
experience from their countries of origin. In addition, the
culture of carrier identification followed by possible prenatal
diagnosis are not usually established in these population
groups. Even when awareness is provided by the new host
country’s services, the decision of immigrants, at least in
the first generation, is greatly influenced by their cultural
and religious background linked to their country of origin
[29, 30].
It is evident that, as a result of heavy past and continued
migrations coupled with projections for future increase, the
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visible public health problem in most of Europe. The new
host countries of Europe appeared initially unprepared for
this new yet increasing problem, and health authorities were
unawareandunwillingtoinvestinservicesforwhatmayhave
beenviewedasatemporarysituation.Withtime,theproblem
g r e wa n dt r e a t m e n ts e r v i c e ss t a r t e dt ob ep r o v i d e di nf e w
centres. Eventually prevention had to also be considered as
t h en u m b e r so fi m m i g r a n t sa n dp o t e n t i a l l yt h en u m b e ro f
annual affected births were increasing. The United Kingdom
was the first among the Northern European states to develop
aspecificprogramandappropriateservices[1],albeitinitially
not at the national level, almost concurrently with the
endemic south. Other countries in the north have since
f o l l o w e d ,b u tm a n ys t i l lh a v eal o n gw a yt og oi no r d e rt o
develop optimal and comprehensive services.
Europe had not experienced the need for developing
genetic programs, which involve the total population to
the same extent as the thalassaemia-endemic areas. The
concept of community genetics has indeed introduced many
concerns including ethical and legal challenges, complicated
by the fact that these hereditary disorders are more common
to immigrant populations with different cultures affecting
the practical application of such programs. Demographic
and epidemiological data are prerequisites and constitute a
priority for development of national programs and services.
The carrier rate may be the same as that of the country of
origin, which is the method to calculate the figures presented
inthisreport,butitwouldhavebeenbetterestimatedbylocal
surveys,whichcouldprovidefiguresonannualaffectedbirths
andthetotalandat-riskpregnancies.Suchinformationcould
offer better or more accurate estimates for the planning of
services as for example the size of the clinical services, the
neededscreeningprogram,thenumberofprenataldiagnoses
to be carried out, and the needs for couples’ counseling [4].
In very few parts of Europe this process has been completed
w h i l ei no t h e r si th a sy e tt ob ef a c e d .
There has been a tendency for immigrants to gather in
specific areas, often forming “ghettoes”. For this reason, a
second priority is micromapping through patient registries,
with information on patient numbers and location so that
needs for clinical and other services are rationally developed
in geographically relevant locations. Clinical services should
follow internationally accepted evidenced-based guidelines
on which local, national, and regional standards of care
could be integrated. It may be difficult for patients with rare
anaemias in large countries to access expert centres of excel-
lence as recommended by the comprehensive management
programs of all currently available guidelines. This need can
be met by networking and development of shared care with
local centres as well as by physician training [31]w i t h i na
comprehensive national policy for chronic and rare diseases.
There is sufficient evidence, especially from survival data
of various birth cohorts, that care in expert centres based
on updated treatment protocols is associated with improved
patient outcomes [17].
Designated treatment centres with access for all patients
e x i s ti nC y p r u s ,I t a l y ,G r e e c e ,a n dt h eU K( Table 4). In
three other countries, only a portion of the patients have
accesstosuchcentres.Inaddition,specializedlaboratoryand
clinicaltestsnecessaryforaddressingandpreventingmedical
complications do not exist in the great majority of countries
and even in reference or expert centres.
Acknowledging the limitation of the current paper, we
w o u l dl i k et on o t et h a tm a n yo ft h er e s e a r c hq u e s t i o n sw e
p o s e di nt h i ss t u d yc a n n o tb ea c c u r a t e l ya n s w e r e db e c a u s e
updates and/or reliable information may be unavailable.
However, it was possible to build a picture of the current
situation in Europe which may help raise awareness in the
medical community and alert health authorities towards
the particular needs in order to respond to the challenges
that come with changes in the population demographics.
DespitetherarityoftheHbdiseases,theirchronicnatureand
complexity result in a significant impact on health planning,
which may lead to devastating and immense economic and
other repercussions on individual patients and families. It
must also be remembered that migrations are not constant
but in fact are changing constantly in terms of size, direction,
and impact, according to historical, environmental, political,
and economic circumstances and therefore are difficult to
follow. Because of this, the conclusions of this study reflect
only on the very current situation and availability of health
services for Hb disorders.
Financing services for Hb disorders is an important
issue common to all chronic diseases’ programs. Appropriate
allocation of financial and human resources is essential for
the sustainability of any such program. Some countries have
adopted copayment systems, which may exert a difficult
burden on migrants and low-income groups facing lifelong
treatment and multidisciplinary care needs. In times of
economic restraints, inequalities in access and health care
s e r v i c e sm a yb em o r el i k e l yt oi n c r e a s ei na na l r e a d yg l o b a l
environment of severe inequalities in the health and social
domains. Migrants with chronic diseases are particularly
vulnerable to such situations.
The planning of programs for these genetic disorders is
a public health exercise, which has not yet been adequately
adopted in all European settings either as chronic disease
policies or rare disease policies (Tables 3, 4,a n d5) .Th i si sa n
unfortunatesituation,sincesufficientknowledge,experience,
and expertise exist to adequately and effectively prevent
and treat Hb disorders. In making plans, health authorities
should also monitor the changes in the size and origins of
incoming populations because changes may be significant
over relatively short periods of time.
It is unquestionable that the prevention and treatment
of thalassaemia and sickle cell disease patients have added
to the health burden in many areas of the world by sig-
nificantly contributing to budgetary constraints. However,
governmentsaroundtheworldandparticularlyinEuropeare
already committed not only by having signed two important
WHO specific resolutions [13, 14]b u ta l s ob ya p p r o v i n g
otherEUdirectivesonmigranthealthandrecommendations
on rare diseases. As a global NGO with responsibility and
commitment for advocacy of patients’ rights, TIF aims to
continue its coordinated efforts to strengthen the support for
thepromotionofpolicieswhichwillresultinbetteroutcomes
for all patients with Hb disorders in the European and global
arena. Each European country has a different approach toThe Scientific World Journal 9
fundingandprovidingcost-effectivesolutionstothemultiple
needs of chronically sick patients, especially among ethnic
minorities. TIF is committed to monitor the progress, raise
awareness, and support the promotion of more immigrant-
oriented health policies to ensure their integration in society
and their access to appropriate, adequate, and timely health
services.
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